P-38 KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma

Authors:
Publisher website
Google Scholar
Abstract
No abstract available
Funding Information
  • Merck Sharp and Dohme United Kingdom